Stryker (SYK)
(Delayed Data from NYSE)
$335.61 USD
-1.54 (-0.46%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $335.50 -0.11 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$335.61 USD
-1.54 (-0.46%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $335.50 -0.11 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Zacks News
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seeking Clues to Stryker (SYK) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Stryker (SYK) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
SYK vs ZBH: Which Stock Looks More Promising Ahead of Q1 Earnings?
by Urmimala Biswas
SYK and ZBH are expected to have witnessed strong procedural volume growth across the global market in the first quarter.
Ongoing Procedural Growth May Aid Stryker's (SYK) Q1 Earnings
by Zacks Equity Research
Stryker's (SYK) first-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Stryker (SYK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Stryker (SYK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein (HSIC) Global Presence Aids, Macroeconomic Woes Stay
by Zacks Equity Research
Henry Schein (HSIC) is busy promoting digital workflows for general dentistry and dental specialties.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors are optimistic about Chemed (CHE), backed by the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
by Zacks Equity Research
Bio-Rad's (BIO) margin performance bears the brunt of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Hologic's (HOLX) New Launches Aid, Macroeconomic Issues Ail
by Zacks Equity Research
Hologic's (HOLX) Breast Health segment is gaining from a broad portfolio of solutions for breast cancer care, primarily in the burgeoning spaces of radiology, breast surgery, pathology and treatment.
Why You Should Add Haemonetics (HAE) to Your Portfolio Now
by Zacks Equity Research
Recovery within the Hospital business and the favorable prospects of the Plasma franchise raise investors' optimism for Haemonetics (HAE).
Smith+Nephew (SNN) Expands in Australia With New Alliance
by Zacks Equity Research
The latest partnership allows Smith+Nephew (SNN) to complement its existing implant range with the cutting-edge navigation technology of NAVBIT.
Align Technology (ALGN) Up 20.5% YTD: Will the Rally Continue?
by Zacks Equity Research
Investors are optimistic about Align Technology (ALGN) driven by geographic expansion and upbeat guidance.
Boston Scientific (BSX) Faces Rising Costs, Competition
by Zacks Equity Research
With Boston Scientific (BSX) recording 40% of its sales from the international market, it remains highly exposed to currency fluctuations.
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.
Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes
by Zacks Equity Research
Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.
Bruker (BRKR) Introduces Magnet Technology for NMR Adoption
by Zacks Equity Research
Bruker's (BRKR) latest novel technology facilitates the widespread application of NMR in academic basic and clinical research.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.
Thermo Fisher (TMO) Launches TSX Universal Series ULT Freezers
by Zacks Equity Research
Thermo Fisher's (TMO) new ENERGY STAR-certified TSX Universal Series ULT Freezers deliver tighter temperature control and faster recovery times.
Abbott (ABT) Faces Low Testing Demand, Currency Headwinds
by Zacks Equity Research
Abbott's (ABT) core laboratory diagnostics business is gaining strength on the continued success of the Alinity suite of diagnostics instruments, along with a broad test menu offering.
IM Cannabis (IMCC) Expands Business in Germany With New Alliance
by Zacks Equity Research
The partnership's core objective is to grant IM Cannabis' (IMCC) subsidiary, Adjupharm GmbH, exclusive rights to introduce Avant's BLK MKT cannabis brand in Germany's medical cannabis market.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strength exhibited in the Thrombectomy business and global expansion.
Labcorp (LH) Extends MRD Clinical Research With New Launch
by Zacks Equity Research
Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
by Zacks Equity Research
Teleflex's (TFX) new UroLift 2 System with the ATC platform is designed to treat all prostate types.
Abbott (ABT) Receives FDA's Approval for the TriClip TEER System
by Zacks Equity Research
Abbott (ABT) receives FDA nod for TriClip, a first-of-its-kind device to repair a leaky tricuspid heart valve.